# Tim Funnell

> Tim Funnell is a Series A investor at Monograph Capital backing Medical. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Monograph Capital](https://shizune.co/investors/profile/monograph-capital)
- Location: Boston, United States
- Total investments: 5
- Last investment: Oct 2025
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/tim-funnell-349a9119/
- X (Twitter): https://twitter.com/timfunnell
- Website: https://x.com/timfunnell

Tim Funnell is a Series A investor at Monograph Capital in Boston focused on Medical and Health Care. Tim Funnell is the Partner of Monograph Capital. He previously worked at MiroBio Ltd as a Founding team: VP, Operations. Tim Funnell attended the University of Oxford.

## Contacts

5 contacts available for Tim Funnell: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/tim-funnell?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 20% |
| Health Care | 1 | 20% |
| Therapeutics | 1 | 20% |
| Biotechnology | 1 | 20% |
| Information Technology | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 3 | 60% |
| United States | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Elevara Medicine | Elevara Medicines addresses a basic issue in rheumatoid arthritis (RA): individuals who fail to achieve disease remission using immune-targeted therapies. Elevara Medicines intends to breach the efficacy barrier that patients face with current immunosuppressive medications. | $70M | Series A | Oct 22, 2025 |  |
| Maxion Therapeutics | Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets. | $75.3M | Series A | Mar 17, 2025 |  |
| Ouro Medicines | Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline. | $120M | Series A | Jan 10, 2025 |  |
| Maxion Therapeutics | Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets. | $15.6M | Series A | Feb 15, 2023 |  |
| AviadoBio | AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK DementiaResearch Institute. | $77.9M | Series A | Dec 02, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund, 3 deals together
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 2 deals together
- [LifeArc Ventures](https://shizune.co/investors/profile/lifearc-ventures) — VC Fund, 2 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 2 deals together
- [Advent Life Sciences](https://shizune.co/investors/profile/advent-life) — VC Fund, 1 deal together
- [Boyu Capital](https://shizune.co/investors/profile/boyu-capital) — VC Fund, 1 deal together

## About Monograph Capital

VC Fund · London, United Kingdom

Monograph Capital is a life sciences venture firm. We find and fund groundbreaking life sciences companies to transform promising science into real, life-changing treatments for people across the world.

3 contacts available at Monograph Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Charles Conn | Co-founder | https://shizune.co/investors/profile/charles-conn-d144 |
| Tim Funnell | Partner | — |
| Bonnie van Wilgenburg | Principal | — |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Tim Funnell invest in?

Tim Funnell invests primarily in Medical, Health Care and Therapeutics startups, most often at Series A stage. Most of the 5 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Tim Funnell?

Public channels for Tim Funnell include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Tim Funnell last invest?

The most recent investment recorded for Tim Funnell closed in Oct 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co